Does Medicare Advantage Cover Wegovy in 2026? Here Are the 3 Real Coverage Paths

The 2026 Wegovy + Medicare Advantage Coverage Map

Sources: CMS Medicare GLP-1 Bridge FAQ (last updated May 6, 2026); KFF analysis of BALANCE Model; FDA Wegovy prescribing information; Wegovy manufacturer savings terms.

Does Medicare Advantage Cover Wegovy in 2026? The Honest Answer

Medicare Advantage covers Wegovy in 2026 when one of three conditions is met: (1) the prescription is for a Part D-covered FDA-approved indication such as cardiovascular risk reduction or MASH and your plan lists Wegovy on its formulary, (2) you qualify for the new Medicare GLP-1 Bridge that starts July 1, 2026, or (3) you pay cash. Standard Part D still cannot cover Wegovy for weight loss alone because a 2003 federal law blocks it.

The rules shifted three times in the last 24 months:

• March 2024: The FDA approved Wegovy for cardiovascular risk reduction in adults with heart disease who are overweight or obese — creating a new, non-weight-loss reason to prescribe it that Medicare could finally cover. FDA announcement
• December 2025: CMS announced the BALANCE Model and the Medicare GLP-1 Bridge to expand obesity coverage through Medicare for the first time. CMS announcement
• April 21, 2026: CMS announced that the BALANCE Model would not launch for Medicare Part D in 2027 — fewer than 80% of Part D plan sponsors agreed to participate. CMS extended the Bridge through December 31, 2027. KFF brief

Path 1 — Wegovy Through Medicare Advantage for a Part D-Covered Indication

If your Wegovy prescription is for cardiovascular risk reduction, MASH, or another FDA-approved indication beyond weight loss, your MA-PD plan may cover it through your normal Part D drug benefit today. Coverage depends on whether your plan's formulary lists Wegovy and whether you pass prior authorization for that specific indication.

The 2003 federal law that blocks Medicare from covering weight-loss drugs only blocks weight-loss-only use. When Wegovy is prescribed for a different FDA-approved indication, that exclusion doesn't apply. Today, Wegovy has three FDA-approved indications relevant to Medicare:

Who qualifies under the cardiovascular indication

Three things generally need to be documented:

1. Established cardiovascular disease. Usually a documented history of a heart attack, stroke, or peripheral artery disease. Plain "high blood pressure" or "high cholesterol" alone often doesn't qualify.
2. BMI of 27 or higher. This is the threshold the FDA used in approving the cardiovascular indication.
3. The indication on file matches the request. Your prescriber needs to document the medically accurate reason. If submitted as weight-management-only under standard Part D, it's likely to be denied.

How to check if your MA-PD plan covers Wegovy under a Part D-eligible indication

What you'll actually pay if your plan covers it

Does Medicare Advantage Cover Wegovy for MASH?

Potentially yes — through regular MA-PD/Part D, not the Medicare GLP-1 Bridge. The FDA label for Wegovy injection includes treatment of noncirrhotic MASH/NASH with moderate-to-advanced liver fibrosis in adults under accelerated approval. If Wegovy is prescribed for that indication and your plan's formulary lists it, MA-PD coverage rules apply. The Bridge does not cover MASH — only weight reduction and maintenance.

Not every plan has updated its formulary to reflect the MASH indication, and prior authorization criteria for MASH are still evolving across carriers. The verification workflow is the same as for the cardiovascular indication — check your plan's drug list, call member services, ask specifically about the MASH indication ("noncirrhotic MASH with moderate-to-advanced liver fibrosis"), and get the answer in writing.

Path 2 — The Medicare GLP-1 Bridge ($50/month, July 1, 2026 – December 31, 2027)

The Medicare GLP-1 Bridge is a federal demonstration program that lets eligible Medicare Advantage members get Wegovy, Zepbound KwikPen, or Foundayo for $50 per month — for weight reduction or maintenance — starting July 1, 2026, through December 31, 2027. Your MA-PD plan does not have to opt in. The Bridge operates outside the normal Part D formulary process, but it does require Bridge prior authorization and CMS clinical eligibility.

What the Bridge actually is

The Bridge is a CMS payment demonstration — not a Part D benefit. Key distinctions:

• Your MA-PD plan doesn't decide whether to participate — it operates outside the normal Part D flow
• The $50 copay doesn't count toward your Part D deductible or your $2,100 out-of-pocket cap
• Manufacturer copay cards and Low-Income Subsidies don't apply during the Bridge
• CMS uses a single central processor (Humana, using LI NET infrastructure) to handle Bridge PA and pharmacy claims nationwide

CMS negotiated a net price of $245 per month with manufacturers (Novo Nordisk for Wegovy/Foundayo, Eli Lilly for Zepbound KwikPen). Manufacturers pay the difference back to CMS directly.

Bridge eligibility — the four things you need

To qualify for the $50/month Wegovy copay through the Bridge, all four must be true:

The 3 clinical tiers (you only need one)

Source: CMS GLP-1 Bridge FAQ, updated May 6, 2026.

Which drugs the Bridge covers

Ozempic and Mounjaro aren't on the Bridge list — they're FDA-approved for type 2 diabetes, not weight loss, and Medicare already covers them for diabetes under standard Part D rules.

How the Bridge prior authorization process works

Starting July 1, 2026, here's the workflow:

Why the Bridge isn't permanent

The Bridge was originally supposed to run July–December 2026, with the broader BALANCE Model taking over for Medicare Part D in January 2027. BALANCE required at least 80% of Part D plan sponsors to opt in. CMS confirmed on April 21, 2026 that the 80% threshold was not met. BALANCE will not launch for Medicare Part D in 2027. CMS extended the Bridge through December 31, 2027. After that, continued access depends on whether CMS revives BALANCE or launches a new program.

Already on a GLP-1? See our Medicare GLP-1 Bridge eligibility guide for the full breakdown.

Path 3 — Cash-Pay Backup If Paths 1 and 2 Don't Fit

Medicare beneficiaries should not assume Wegovy's advertised manufacturer self-pay prices are available to them. Wegovy's official terms — including the $25/month Wegovy Savings Card AND the NovoCare cash-pay tiers — explicitly exclude Medicare, Medicaid, TRICARE, VA, and DoD beneficiaries. That's federal anti-kickback law combined with manufacturer policy. The pharmacy will catch it at the counter.

The real cash routes for Medicare beneficiaries are:

1. The retail-pharmacy cash price for Wegovy without any manufacturer assistance — typically around $1,349/month at list price.
2. A telehealth provider's cash-pay program with independent pricing the provider sets — not tied to NovoCare's restricted savings tier. The provider's published terms determine whether Medicare members can use the program; verify before signing up.

Cash-pay telehealth options for Medicare Advantage members (verified May 2026)

Provider data from published pricing pages, verified May 2026. Verify on provider's current site before signing up.

Which Medicare Advantage Plan Types Qualify for Bridge Access?

Not every Medicare Advantage plan type qualifies for the Medicare GLP-1 Bridge. Standard MA-PD plans (HMO, HMOPOS, Local PPO, Regional PPO) are eligible, along with Special Needs Plans and most employer/union group plans. Private Fee-for-Service plans, Medical Savings Account plans, PACE plans, and a few other niche plan types are not eligible — even if they include drug coverage.

MA Plan Type Bridge Eligibility Matrix (Verified May 6, 2026)

Source: CMS Medicare GLP-1 Bridge FAQ, last updated May 6, 2026.

What to do if your plan type isn't eligible

1. If your current plan type allows it, pair with a standalone Part D drug plan — possible for some PFFS plans, MSAs, and Cost Plans. Confirm with Medicare.gov.
2. Switch to a standard MA-PD plan during the Annual Enrollment Period (October 15 – December 7, 2026 for 2027 coverage) or the Medicare Advantage Open Enrollment Period (January 1 – March 31).

How Major Medicare Advantage Carriers Are Handling Wegovy in 2026

Carrier-level coverage claims are not reliable enough on their own for a Medicare Advantage decision because formularies vary by plan, county, pharmacy network, and indication. Use this as a verification workflow, not as a carrier promise.

• Medicare Advantage plans cannot cover Wegovy for weight loss alone under standard Part D — that rule applies to every MA-PD carrier without exception.
• CVS Caremark — the PBM behind many MA-PD plans including most Aetna plans — has publicly listed Wegovy as the preferred GLP-1 on its 2026 formularies, with Zepbound excluded from most CVS Caremark commercial formularies.
• Humana is the Bridge central processor using LI NET infrastructure — every Bridge prior authorization and claim routes through Humana, regardless of which MA carrier issued your plan card.

Your 4-question carrier verification script

1. "Is Wegovy on my plan's 2026 formulary, and for which indications? Please confirm whether the cardiovascular risk reduction indication is covered, and whether the MASH liver disease indication is covered."
2. "What tier is Wegovy on, and what's my coinsurance or copay?"
3. "What documentation does the prior authorization require, and is step therapy applied?"
4. "After July 1, 2026, will weight-loss prescriptions for Wegovy be routed to the Medicare GLP-1 Bridge central processor, and what should my prescriber submit?"

Get answers in writing. Save the date, time, and rep's name.

How to Get Wegovy Approved Through Medicare Advantage Prior Authorization

Prior authorization is the single biggest reason eligible Medicare Advantage members don't end up with Wegovy coverage. Per KFF analysis, only about 11.5% of denied MA prior authorization requests were appealed in 2024, and 80.7% of appealed denials were partially or fully overturned. Most people give up after the first denial without realizing they were close.

What If Your Medicare Advantage Plan Denies Wegovy?

Common denial reasons: diagnosis on file doesn't match the requested indication, insufficient documentation, missing BMI records, step therapy requirements not yet met, and the drug not being on the plan's formulary. Some denials are fixable. Others are true non-coverage decisions.

Does Medicare Advantage Cover Wegovy Pill or Wegovy HD?

Wegovy tablets (FDA-approved December 22, 2025) are covered under the Bridge at $50/month. Wegovy HD (the 7.2 mg high-dose injection, FDA-approved March 2026) is FDA-approved for weight reduction and maintenance — CMS lists all Wegovy formulations as Bridge-eligible. Coverage of Wegovy HD under regular Part D depends on your plan's formulary and the FDA-approved indication — verify before assuming.

If needles are the dealbreaker, the Wegovy pill is a real option in 2026 that didn't exist in 2024. More on Wegovy pill vs. injection in our deep-dive guide.

AEP and MA OEP — When to Switch Plans to Get Better Wegovy Coverage

If your current plan won't cover Wegovy for the CV or MASH indication, or your plan type isn't Bridge-eligible, you can switch during the Annual Enrollment Period (October 15 – December 7) or the Medicare Advantage Open Enrollment Period (January 1 – March 31).

Should you switch plans for Wegovy? Decision table

What Wegovy Actually Costs Under Each Medicare Advantage Path (May 2026)

All pricing verified May 2026 against CMS, FDA, and Wegovy manufacturer published terms. Specialty tier coinsurance percentage varies by plan (typically 25–33%).

What We Verified for This Page

Frequently Asked Questions

Does Medicare Advantage cover Wegovy for weight loss in 2026?

Standard MA-PD coverage of Wegovy for weight loss alone remains excluded under the 2003 Medicare Modernization Act. Starting July 1, 2026, eligible MA-PD members can get Wegovy for weight reduction or maintenance at $50/month through the Medicare GLP-1 Bridge after Bridge prior authorization. Whether the Bridge applies depends on your plan type eligibility, CMS's BMI/condition criteria, and Bridge PA approval — it's not automatic.

Will Medicare Advantage cover Wegovy if I have heart disease?

Possibly yes — Medicare Advantage may cover Wegovy under the cardiovascular indication if you have established cardiovascular disease and a BMI of 27 or higher, and your plan's formulary lists Wegovy for that use. Coverage depends on prior authorization and supporting documentation tying the prescription to the cardiovascular indication.

Does Medicare Advantage cover Wegovy for MASH?

Potentially yes, through regular MA-PD/Part D — not the Medicare GLP-1 Bridge. The FDA label for Wegovy injection includes treatment of noncirrhotic MASH/NASH with moderate-to-advanced liver fibrosis under accelerated approval. Coverage depends on your plan formulary and prior authorization criteria for that specific indication.

How much does Wegovy cost on Medicare Advantage?

Under a Part D-covered indication, Wegovy typically costs $325–$430/month in specialty tier coinsurance until you hit the $2,100 Part D out-of-pocket cap, after which it's free for the rest of the year. Under the Medicare GLP-1 Bridge starting July 1, 2026, it's $50/month flat. Cash-pay backup pricing varies — Medicare beneficiaries cannot use Wegovy's manufacturer self-pay tiers.

Can Medicare Advantage members use NovoCare self-pay pricing or the Wegovy Savings Card?

No. Wegovy's manufacturer savings and self-pay offers — including the $25 Savings Card and the NovoCare cash-pay tiers — explicitly exclude government beneficiaries, including Medicare and Medicare Advantage members. That's federal law combined with manufacturer policy. Cash-pay options for Medicare beneficiaries have to be verified separately from manufacturer savings offers.

Does the $50 Bridge copay count toward my Part D out-of-pocket cap?

No. The Bridge operates outside the normal Part D coverage and payment flow. The $50 copay does not count toward your Part D deductible, your TrOOP (true out-of-pocket), or your $2,100 annual out-of-pocket cap. Low-Income Subsidy reductions also do not apply to the Bridge copay.

What Medicare Advantage plans cover Wegovy in 2026?

Wegovy is on many MA-PD plan formularies for FDA-approved indications other than weight loss — including cardiovascular risk reduction and MASH — but specific tier placement and prior authorization criteria vary by plan, county, and year. The Medicare GLP-1 Bridge runs centrally through CMS starting July 1, 2026 and is available regardless of which carrier issued your MA-PD plan, as long as your plan type is Bridge-eligible.

Can Ro handle my Medicare Advantage prior authorization for Wegovy?

Per Ro's published terms, Ro currently can't help coordinate GLP-1 coverage for government insurance plans (with a narrow FEHB exception). For Medicare Advantage prior authorization, work directly with your MA-PD plan, your prescriber's PA team, and — for weight-management requests after July 1, 2026 — the Bridge central processor. Ro can still be a cash-pay FDA-approved option for Medicare members who choose to pay outside insurance.

Is the Wegovy pill covered by Medicare Advantage?

Wegovy tablets (FDA-approved December 22, 2025) are covered under the Medicare GLP-1 Bridge at $50/month. Coverage under regular Part D depends on your plan's formulary and the indication on the prescription.

What if my Medicare Advantage plan denies Wegovy?

Appeal it. Per KFF analysis of CMS MA data, only about 11.5% of denied MA prior authorization requests were appealed in 2024, and 80.7% of appealed denials were partially or fully overturned. That figure is MA-wide, not Wegovy-specific, but it's a useful reason not to treat a first denial as final. Many successful appeals resolve at level 1 or 2 of the 5-level Medicare appeal process. If your Part D denial was for a weight-management prescription, the Bridge process starting July 1, 2026 may be the parallel path that works.

Can I switch Medicare Advantage plans to get Wegovy coverage?

Yes, during the Annual Enrollment Period (October 15 – December 7) or the Medicare Advantage Open Enrollment Period (January 1 – March 31). Switching doesn't change federal rules about Wegovy coverage, but it can give you a plan that lists Wegovy on its formulary or that has a Bridge-eligible plan type.

What happens to Wegovy coverage after the Bridge ends in December 2027?

After December 31, 2027, continued $50/month access depends on whether CMS revives the BALANCE Model for Medicare Part D or launches a new coverage mechanism. Watch for announcements during the fall 2027 Annual Enrollment Period. Part D coverage of Wegovy for non-weight-loss FDA-approved indications continues regardless.

Still not sure which path fits you?

If any of these is true, your right next step depends on details we can't see from here:

• You have heart disease or MASH and want to explore the Part D-covered indication path
• You meet the Bridge BMI criteria and want to be ready July 1, 2026
• Your plan denied you and you want to know if it's worth appealing
• You're considering switching plans during the next AEP
• You're in a Medicare Advantage plan type that isn't Bridge-eligible

For deeper reading:

• Medicare GLP-1 Bridge eligibility guide
• Broader Medicare + Wegovy coverage guide
• Wegovy pill vs. injection comparison
• Wegovy Savings Card and Medicare rules
• Does Medicare cover Zepbound?